Dexcom rises after quarterly sales beat estimates

Shares of medical device maker Dexcom DXCM.O rise 3.9% to $72.98 premarket

Late on Thursday, co posted Q1 sales of $1.04 bln, above analysts' est of $1.02 bln - LSEG

Co reiterated its annual sales forecast of $4.60 bln; analysts were expecting 2025 sales of $4.61 bln - LSEG

J.P.Morgan analyst Robbie Marcus said the co has taken a "conservative approach" and expects to see "outperformance over the balance of the year"

Co reports Q1 adj profit of 32 cents/share, compared with est of 33 cents/share - LSEG

As of last close, stock down 9.7% YTD